AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03829904
Drug: VGH-BPH1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A scientific Chinese granule powder
Trial: NCT00427050
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04111445
Drug: ADG116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion at Day 1 of each cycle
Trial: NCT01233791
Drug: Placebo Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be asked to use one vaginal suppository every night for 28 days
Trial: NCT00060450
Drug: nitric oxide for inhalation
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
Trial: NCT00060450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
Trial: NCT00615966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, IV
Trial: NCT01558154
Drug: Chinese herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbs special for depression
Trial: NCT01453595
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily
Trial: NCT00052468
Drug: TCG
RxNorm normalized name: TCGF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00052468
Drug: TC
RxNorm normalized name: PTC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03077724
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive Oil capsules
Trial: NCT03204097
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis followed by placement of placebo gel
Trial: NCT00755989
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel without morphine
Trial: NCT01318226
Drug: ATx08-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
Trial: NCT01318226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
Trial: NCT02621931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Trial: NCT03312556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill or patch. Single dose
Trial: NCT03747926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-rising oral dose
Trial: NCT04232423
Drug: Placebo ORAL TABLET
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4
Trial: NCT00159211
Drug: UMULINE NPH
RxNorm normalized name: humulene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
Trial: NCT03719105
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
Trial: NCT03719105
Drug: pralatraxate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Trial: NCT03719105
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Trial: NCT03719105
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Trial: NCT02486926
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
Trial: NCT00709280
Drug: 7% Hypertonic Saline (HS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Trial: NCT00709280
Drug: 0.9% Isotonic Saline (IS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Trial: NCT04066114
Drug: mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
Trial: NCT00208793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03489616
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other chemotherapy drugs,such as Docetaxel, gemcitabine
Trial: NCT04323852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00089726
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01060293
Drug: Low-dose furosemide combined with low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
Trial: NCT03731468
Drug: local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound guided superficial cervical block in thyroid surgery
Trial: NCT00046358
Drug: Lovostatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00046358
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04184063
Drug: NBMI
RxNorm normalized name: N-Benzyl-D-glucamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBMI active treatment
Trial: NCT02313467
Drug: Topical application of 1.5% Butenyl ALA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02779153
Drug: Acthar low dose (40 U)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
Trial: NCT00463710
Drug: Avonex® monotherapy (6.0 MIU administered i.m. each week)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02293629
Drug: Placebo matching BMS-986147
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01605617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTNS + placebo for 12 weeks
Trial: NCT00075738
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00075738
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00797797
Drug: No Treatment Added
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No added treatment
Trial: NCT01726413
Drug: GRC 17356
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01726413
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02737735
Drug: standard chemotherapy medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01695850
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
Trial: NCT03583372
Drug: placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match vibegron (experimental drug) and tolterodine (active comparator)
Trial: NCT02769169
Drug: Lucentis® (Raibizumab) double-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
Trial: NCT02769169
Drug: Lucentis® (Raibizumab) regular-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
Trial: NCT04161001
Drug: Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
Trial: NCT04161001
Drug: Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
Trial: NCT00396240
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02071004
Drug: DS-1040b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV of 6 mg given once over 30 minutes
Trial: NCT05439460
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
Trial: NCT02854904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo controlled
Trial: NCT00903747
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (Group 2b)
Trial: NCT00315250
Drug: [123I]β-CIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Trial: NCT03810209
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adding normal saline to local anaesthetic in SAP block
Trial: NCT04416269
Drug: Oral Anti-diabetes Drugs alone
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
Trial: NCT03457532
Drug: Gumarontinib Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
Trial: NCT01672801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02273141
Drug: NER1006, Day Before-Only Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
Trial: NCT02273141
Drug: SP+MS, Day Before-Only Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
Trial: NCT02774057
Drug: Captafer®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems
Trial: NCT02774057
Drug: Iron Sulfate
RxNorm normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 195 mg Iron supplement
Trial: NCT01673802
Drug: CT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoxetate (Eovist) enhanced dual energy CT
Trial: NCT00934466
Drug: MK2637
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 120 mg MK2637 capsules in one of five treatment periods.
Trial: NCT00934466
Drug: Comparator: MK2637
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 50 mg MK2637 capsules in one of five treatment periods.
Trial: NCT00934466
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo only in one of five treatment periods.
Trial: NCT02959437
Drug: INCB057643
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Trial: NCT02959437
Drug: INCB059872
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Trial: NCT02486328
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage adjustment
Trial: NCT01143948
Drug: Glargine & Glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal Glargine \& bolus Glulisine
Trial: NCT01143948
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding scale regular insulin
Trial: NCT01143948
Drug: NPH & regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal NPH \& bolus regular insulin
Trial: NCT01494402
Drug: Buffered acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04053764
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
Trial: NCT01592409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
Trial: NCT01734681
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00790738
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04325659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
Trial: NCT00890955
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
Trial: NCT00220766
Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03185611
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: immunomodulator
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Trial: NCT04213196
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
Trial: NCT02232893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
Trial: NCT02242747
Drug: 5% 5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two applications a day for four weeks in a pre-determined area
Trial: NCT01044004
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 150mg/day for 13 weeks
Trial: NCT04721054
Drug: Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
Trial: NCT04721054
Drug: general anesthesia effect on heart rate in Laparoscopic Cholecystectomy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
Trial: NCT02293538
Drug: FID 114657 eye drops (10 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
Trial: NCT02293538
Drug: Saline control eye drops (15 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline eye drops (15 ml)